The overexpression of the human epidermal growth factor receptor 2 (HER2) is a predictive
biomarker in therapeutic effects for metastatic breast cancer. Accurate HER2 testing is …

Simple Summary Early detection and personalized treatment for breast cancer are vital for
breast cancer patients survival. Computational pathology approaches can be employed by …

Human epidermal growth factor receptor 2 (HER2) gene amplification helps identify breast
cancer patients who may respond to targeted anti-HER2 therapy. This study aims to develop …

Simple Summary HER2 expression is important for target therapy in breast cancer patients,
however, accurate evaluation of HER2 expression is challenging for pathologists owing to …

Overexpression of human epidermal growth factor receptor 2 (HER2/ERBB2) is identified as
a prognostic marker in metastatic breast cancer and a predictor to determine the effects of …

Background Novel anti-HER2 antibody drug conjugates (ADCs) have shown efficacy in
breast cancers (BCs) expressing low levels of HER2 (ie, IHC 1+/2+). A subset of BCs …

Background HER2 is an important predictive biomarker of HER2-targeted therapies for
breast cancer. Reliable HER2 testing is essential for clinical practice, but …

The human epidermal growth factor receptor 2 (HER2) gene amplification status is a crucial
marker for evaluating clinical therapies of breast or gastric cancer. We propose a deep …

Tissue biomarker scoring by pathologists is central to defining the appropriate therapy for
patients with cancer. Yet, inter-pathologist variability in the interpretation of ambiguous …

The expression of human epidermal growth factor receptor 2 (HER2) protein or gene
transcripts is critical for therapeutic decision making in breast cancer. We examined the …